Pomalyst (Bristol Myers Squibb) has faced US generic competition since 2026. US generics launched March 2026 under settlements.
Pomalyst's US exclusivity date is based on generics launched. US generics have already launched, so the loss of exclusivity is under way. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.
Pomalyst was selected for the Medicare Drug Price Negotiation Program. Its negotiated Medicare price takes effect in 2027, 60% below its list price. US generics had already launched by then. The discount is measured against list price, before the rebates drugmakers already pay, and applies to Medicare only, so the revenue impact is smaller than the headline number.
Breckenridge launched generic pomalidomide under the settlement timeline, with Camber following. Breckenridge
Pomalyst is 5.7% of Bristol Myers Squibb's 2025 revenue ($2.7B of $48.2B). With Eliquis and Opdivo, the drugs tracked here add up to 56% of Bristol Myers Squibb's revenue losing US exclusivity by 2028.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Pomalyst is highlighted.